The access that patients have to information nowadays is an opportunity for companies to integrate their direct feedback, says CSL Behring’s head for Europe.
PPD puts the spotlight on special patient populations by supporting clinical trials with Asian participants, preparing developers to expand into the Asian market.
Early dialogue with patients is ‘critical’ to design efficient clinical development programs for ATMPs and avoid ‘data gaps’, an executive from ARM says.
Iqvia’s Orchestrated Patient Engagement solution, powered by Belong.Life, delivers ‘hyper-personalized’ content to engage and support patients, providing insights that will benefit patients, life sciences companies, and the health care system, says CEO.
Capital Health joins Kiyatec’s clinical trial to validate a patient-specific predictor test to improve response to cancer therapies for glioblastoma and anaplastic astrocytoma.
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
Females as caregivers, clinical trial participants, and biopharma leaders are among the different roles to be carefully considered as the industry aims for increased inclusion, says BBK executive.
The HIPAA-compliant patient engagement digital platform was developed for clinical trial participants who recently joined or finished a study, providing resources across a range of health conditions.
Parexel forms a strategic partnership with Clariness to deploy the ClinLife platform in the Greater China area as the CRO looks to recruit and engage patients in their native language and via social media channels.
Trialbee and Linical Accelovance join forces for patient-centric clinical trials using digital innovations to establish a single point of contact to expedite clinical trial enrollment, retention, and speed-to-market solutions.
With the recent marriage between technology and science aimed at innovating aspects of clinical trials panels composed of experts from fields outside of pharma could prove to be impactful.
